Drug Profile

ALN SNCA

Alternative Names: ALN-SNCA

Latest Information Update: 20 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alnylam Pharmaceuticals
Developer Regeneron Pharmaceuticals
Class Antiparkinsonians; Drug conjugates; Small interfering RNA
Mechanism of Action Alpha-synuclein expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Parkinson's disease

Most Recent Events

05 Dec 2025 Phase-I clinical trials in Parkinson's disease (Treatment-naive, Early-stage disease) in Netherlands (Intrathecal) (NCT07216066)
14 Oct 2025 Preclinical trials in Parkinson's disease in USA (Intrathecal), before October 2025
14 Oct 2025 Regeneron Pharmaceuticals plans phase I trial in Parkinson's Disease in November 2025 (Intrathecal) (NCT07216066)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com